Vancouver, BC — May 30, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today commented on President Obama’s National Alzheimer’s Plan, which was unveiled earlier this month. It is part of the National Alzheimer’s Project Act (NAPA), which was signed into law in January 2011. NAPA is the first-ever national plan to address Alzheimer’s disease. …
Palo Alto, CA — February 14, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL)today announced that Dr. George F. Tidmarsh, MD, PhD, Executive Director, is scheduled to present a corporate update at the BIO CEO & Investor Conference in New York. Dr. Tidmarsh’s presentation will be webcast live and takes place on Tuesday, February…
Hoboken, NJ — November 14, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced the successful completion of its Phase 1 single ascending dose (SAD) clinical trial of ANAVEX 2-73, the company’s lead drug candidate for the treatment of Alzheimer’s Disease (AD). ANAVEX 2-73 is the first of a new class of oral…
Hoboken, NJ — October 12, 2011 — Anavex Life Sciences Corp., (“Anavex”) today announced the appointment of Dr. George Tidmarsh as director, and his engagement to act as an executive director. Dr. Tidmarsh is an executive-level physician/scientist and consultant who has founded and built several successful biotechnology companies. He has more than 20 years of…
HOBOKEN, NJ, September 16, 2011 – Anavex Life Sciences Corp. (“Anavex”) reports that Dr. Cameron Durrant has resigned as Director and Executive Chairman of the Board effective immediately. Anavex’s Board of Directors would like to thank Dr. Durrant for his contributions to the company and wish him well in his future endeavors. About Anavex Life…
Hoboken, NJ — September 15, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) will present the most recent data showing the therapeutic potential of ANAVEX compounds in animal models of Alzheimer’s disease at a special symposium of the 34th annual meeting of the Japan Neuroscience Society. The symposium is being held inYokohama,Japan from September…
Hoboken, NJ — July 26, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to provide a summary of its second poster presentation at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “Preclinical development of new tetrahydrofuran derivatives targeting the sigma-1 chaperone protein as neuroprotectants in Alzheimer’s disease.” Neuroprotective, anti-amnesic, anti-depressive…
Hoboken, NJ — July 25, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to provide a summary of the first of two poster presentations at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “The novel aminotetrahydrofuran derivative ANAVEX 2-73 attenuated GSK-3beta and Tau hyperphosphorylation in a nontransgenic Alzheimer’s disease model…
Hoboken, NJ — July 15, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease (AD) currently in Phase I clinical trials, will be presented in two poster sessions at the 2011 Alzheimer’s Association International Conference on Alzheimer’s Disease (AAICAD) in…
Hoboken, NJ — July 11, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to announce that it has raised $1,575,000 through the exercise of warrants. Funds will be used to continue the Phase I clinical trial of ANAVEX 2-73, the company’s lead drug candidate for Alzheimer’s disease, to advance other compounds in…
